Budget Increase For NIH Won't Meet Expectations

WASHINGTON--The 6 percent increase requested for the National Institutes of Health in 1992 would provide enough funds to support 632 more research grants but not enough, say science policy analysts, to put federally supported biomedical research on firm financial footing. Given the sorry state of the economy and the huge federal deficit, scientists as well as members of Congress are praising the president's proposed $8.78 billion NIH budget as a step in the right direction. But agency official

Written byElizabeth Pennisi
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Given the sorry state of the economy and the huge federal deficit, scientists as well as members of Congress are praising the president's proposed $8.78 billion NIH budget as a step in the right direction. But agency officials say it's not large enough to allow them to fund at least 6,000 new grants each year, a goal that Congress has urged NIH to adopt and that many researchers feel is vital to the continued health of academic biomedical science (The Scientist, Sept. 3, 1990, page 1; and Jan. 7, 1991, page 6). During the past decade, NIH has stretched its research dollar by levying across-the-board cuts, called downward negotiations, on grants already approved for funding. Each year the average percentage cut has risen, reaching nearly 15 percent last year. At that point, Congress issued a call to stop this practice.

NIH officials have complied. From now on, says acting NIH ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies